Health
CureVac’s Covid-19 vaccine induces immune response in study – Clinical Trials Arena
CureVac has reported that the ongoing Phase I study of its Covid-19 vaccine candidate CVnCoV showed that it was well-tolerated across all tested doses ranging from…
CureVac has reported that the ongoing Phase I study of its Covid-19 vaccine candidate CVnCoV showed that it was well-tolerated across all tested doses ranging from 2 to 12µg and induced strong binding and neutralising antibody responses.
The Phase I study is evaluating the safety, reactogenicity and immunogenicity of the investigational vaccine CVnCoV, an optimised, non-chemically modified mRNA that encodes the prefusion stabilised full-length spike protein of the SARS-CoV-2 virus.
Its mode of action…
-
Noosa News12 hours agoMotorbike rider dies after car collision at Kidaman Creek, west of Sunshine Coast
-
Business23 hours agoWhat I’d buy before the ASX rebounds: 3 high-conviction share picks
-
Noosa News22 hours agoMan shot in the leg during attempted break-in at Beenleigh, Queensland
-
General13 hours agoDemocratic senators want an investigation into potential market manipulation from Trump’s inner circle